Perrigo named German packaging firm executive Uwe Rohrhoff as CEO, replacing John Hendrickson, effective Jan. 15. The former head of Gerresheimer will bring experience leading a global business that included 36 manufacturing facilities across 14 countries and sales of $1.7bn.
The experience Perrigo Co. PLC’s next chief executive, Uwe Rohrhoff, has leading a global firm that provides pharmaceutical packaging points to improving the OTC private label giant's operations and organization, analysts anticipate.
An early item on Rohrhoff's to-do list when he joins Perrigo on Jan. 15 likely will be considering whether the...
The Pink Sheet explores how regulatory approvals for Leqembi differ around the world, and looks at what is coming next.
If US tariffs on pharmaceutical supply chain products come into force they could be disruptive for companies. Ewan Townsend, of the international law firm Arnold & Porter, explains how companies can mitigate issues through negotiating with suppliers and reallocating tariff responsibilities.
The European Medicines Agency says that a regulatory reliance pilot that it is supporting to speed up assessments of post-approval changes appears to be accelerating evaluation timelines in non-EU countries.
The International Council for Harmonisation has identified four new topics that can benefit from global regulatory alignment, with timelines for initiating work to be determined later.
The EU product information for Novo Nordisk’s semaglutide medicines is to be updated to include non-arteritic anterior ischemic optic neuropathy as a side effect with a frequency of “very rare.”
The Pink Sheet explores how regulatory approvals for Leqembi differ around the world, and looks at what is coming next.
FDA regulation was painted as an obstacle to US dominance in the cell and gene therapy space even as panelists at an agency event praised the Office of Therapeutic Products' track record under Nicole Verdun.
